

Direct Line: 01623 672232
Our Ref: 1154
E-mail: sfh-tr.foi.requests@nhs.net

King's Mill Hospital
Mansfield Road
Sutton in Ashfield
Nottinghamshire
NG17 4JL

31st October 2025

Tel: 01623 622515
Join today: www.sfh-tr.nhs.uk

[REDACTED]

Dear Sir/Madam

Freedom of Information Act (FOI) 2000 - Request for Information Reference: FOI
Request on Oncology Lung Cancer

I am writing in response to your request for information under the FOI 2000.

I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

Home, Community, Hospital.

FOI Request / Question	Question Response	Is there an exemption?	Exemption	Exemption Details
Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) • Amivantamab Monotherapy • Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) • Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel • Atezolizumab monotherapy (subcutaneous injection only) • Dabrafenib + Trametinib • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin • Durvalumab • Gemcitabine	Data period is for 01-Jun-25 to 31-Aug-25 • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) – 0 Patients • Amivantamab Monotherapy – 0 Patients • Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) – 0 Patients • Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel – 0 Patients • Atezolizumab monotherapy (subcutaneous injection only) – 0 Patients • Dabrafenib + Trametinib – 0 Patients • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin – 0 Patients • Durvalumab – 0 Patients • Gemcitabine – 0 Patients • Nintedanib + Docetaxel – 0 Patients • Nivolumab – 0 Patients • Osimertinib – 0 Patients • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) – 0 Patients • Paclitaxel – 0 Patients			

• Nintedanib + Docetaxel • Nivolumab • Osimertinib • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) • Paclitaxel • Pembrolizumab Monotherapy • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) • Pemetrexed + Platinum (Carboplatin/Cisplatin) • RET Inhibitors (Pralsetinib, Selpercatinib) • Sotorasib • Tepotinib • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin • Other active systemic anti-cancer therapy • Palliative care only	• Pembrolizumab Monotherapy – 0 Patients • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) – 0 Patients • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) – 0 Patients • Pemetrexed + Platinum (Carboplatin/Cisplatin) – 0 Patients • RET Inhibitors (Pralsetinib, Selpercatinib) – 0 Patients • Sotorasib – 0 Patients • Tepotinib – 0 Patients • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin – 0 Patients • Other active systemic anti-cancer therapy – 0 Patients • Palliative care only – 0 Patients • Amivantamab with carboplatin and pemetrexed – 0 Patients • Cemiplimab with platinum-based chemotherapy – 0 Patients • Adagrasib – 0 Patients • Datopotamab deruxtecan – 0 Patients • Amivantamab with lazertinib – 0 Patients			
---	---	--	--	--

• Amivantamab with carboplatin and pemetrexed • Cemiplimab with platinum-based chemotherapy • Adagrasib • Datopotamab deruxtecan • Amivantamab with lazertinib				
Q2. Does your trust participate in any clinical trials for Non-Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part.	No			

I trust this information answers your request. Should you have any further enquiries or queries about this response please do not hesitate to contact me. However, if you are unhappy with the way in which your request has been handled, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Sally Brook Shanahan, Director of Corporate Affairs, King's Mill Hospital, Mansfield Road, Sutton in Ashfield, Nottinghamshire, NG17 4JL or email sally.brookshanahan@nhs.net.

If you are dissatisfied with the outcome of the internal review, you can apply to the Information Commissioner's Office, who will consider whether we have complied with our obligations under the Act and can require us to remedy any problems. Generally, the Information Commissioner's Office cannot decide unless you have exhausted the internal review procedure. You can find out more about how to do this, and about the Act in general, on the Information Commissioner's Office website at: <https://ico.org.uk/your-data-matters/official-information/>.

Complaints to the Information Commissioner's Office should be sent to FOI/EIR Complaints Resolution, Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. Telephone 0303 1231113, email casework@ico.org.uk.

If you would like this letter or information in an alternative format, for example large print or easy read, or if you need help with communicating with us, for example because you use British Sign Language, please let us know. You can call us on 01623 672232 or email sfh-tr.foi.requests@nhs.net.

Yours faithfully

Information Governance Team

All information we have provided is subject to the provisions of the Re-use of Public Sector Information Regulations 2015. Accordingly, if the information has been made available for re-use under the [Open Government Licence](#) (OGL) a request to re-use is not required, but the licence conditions must be met. You must not re-use any previously unreleased information without having the consent from Sherwood Forest Hospitals NHS Foundation Trust. Should you wish to re-use previously unreleased information then you must make your request in writing. All requests for re-use will be responded to within 20 working days of receipt.